Loading...
 
Translate Register Log In Login with facebookLogin and Register

Alzheimer’s Disease is associated with genes which restrict vitamin D – Aug 2015

 

Vitamin D and Alzheimer’s Disease: Neurocognition to Therapeutics

International Journal of Alzheimer’s Disease Volume 2015, Article ID 192747, 11 pages http://dx.doi.org/10.1155/2015/192747
Anindita Banerjee,1,2 Vineet Kumar Khemka,1,2 Anirban Ganguly,2 Debashree Roy,2 Upasana Ganguly,2 and Sasanka Chakrabarti1
1 Department of Biochemistry, ICARE Institute of Medical Sciences and Research, Haldia 721645, India 2Department of Biochemistry, Institute of Post Graduate Medical Education and Research, Kolkata 700020, India
Correspondence should be addressed to Anindita Banerjee; anny.banerjee at gmail.com



Image Image


Alzheimer’s disease (AD), the major cause of dementia worldwide, is characterized by progressive loss of memory and cognition. The sporadic form of AD accounts for nearly 90% of the patients developing this disease. The last century has witnessed significant research to identify various mechanisms and risk factors contributing to the complex etiopathogenesis of AD by analyzing postmortem AD brains and experimenting with animal and cell culture based models. However, the treatment strategies, as of now, are only symptomatic. Accumulating evidences suggested a significant association between vitamin D deficiency, dementia, and AD. This review encompasses the beneficial role of vitamin D in neurocognition and optimal brain health along with epidemiological evidence of the high prevalence of hypovitaminosis D among aged and AD population. Moreover, disrupted signaling, altered utilization of vitamin D, and polymorphisms of several related genes including vitamin D receptor (VDR) also predispose to AD or AD-like neurodegeneration.
This review explores the relationship between this gene-environmental influence and long term vitamin D deficiency as a risk factor for development of sporadic AD along with the role and rationale of therapeutic trials with vitamin D. It is, therefore, urgently warranted to further establish the role of this potentially neuroprotective vitamin in preventing and halting progressive neurodegeneration in AD patients.

 Download the PDF from VitaminDWiki

Clipped from PDF

  • Despite several experimental in vivo or in vitro models of AD explaining its molecular pathogenesis which have led to different types of drug treatment strategies and tests in animal and cell-based models and in clinical trials, the treatment of AD in general is terribly inadequate at present.
  • A 7-year follow-up study by Annweiler et al. confirms that higher vitamin D dietary intake was associated with lower risk of developing AD among older women [94].
  • The AD-IDEA trial, a randomized placebo- controlled trial, was the first of such trials, on the effectiveness of vitamin D in ADRD patients [118].
  • The trial of vitamin D alone or in combination with other agents/anti-AD drugs have shown positive results in some recent works. Fiala and Mizwicki have shown that combined use of vitamin D3 and DHA . . .
  • In contrast, one randomized control by Stein et al. showed that neither cognition nor disability changed significantly after high-dose vitamin D in mild to moderately severe AD cases [121]
  • [121] M. S. Stein, S. C. Scherer, K. S. Ladd, and L. C. Harrison, “A randomized controlled trial of high-dose vitamin D2 followed by intranasal insulin in Alzheimer’s disease,” Journal of Alzheimer’s Disease, vol. 26, no. 3, pp. 477-484, 2011.
    Note by VitaminDWiki: the study used less than 6,000 IU D2 for only 8 weeks, and kept vitamin D levels < 70 ng.
    Suspect far more Vitamin D is needed when the Vitamin D genes partially block the Vitamin D getting to the cells
    Note: The cure of Multiple Sclerosis, another disease which is hampered by Vitamin D genes, achieves a 150 nanograms of Vitamin D
  • (from conclusion) However, it is worth noting that a very recent study has identified vitamin D binding protein to be a potential blood biomarker for the diagnosis of AD [125].However, further verification with larger epidemiological and molecular evidences is eagerly awaited before targeting DBP as a possible therapeutic modulation in AD.
  • [125] R. J. Bishnoi, R. F. Palmer, and D. R. Royall, “Vitamin D binding protein as a serum biomarker of Alzheimer’s disease,” Journal of Alzheimer’s Disease, vol. 43, no. 1, pp. 37-45, 2015.

VDR Taql problem increases by 1.4 the risk of Alzheimer’s disease - 2016

A TaqI polymorphism of vitamin D receptor is associated with Alzheimer’s disease in Korean population: a case-control study
Int J Clin Exp Med 2016;9(10):19268-19279 www.ijcem.com /ISSN:1940-5901/IJCEM0029304
 Download the PDF from VitaminDWiki


See also VitaminDWiki

Alzheimers-Cognition - Overview has the following summary


Pages listed in BOTH of the categories Cognition and Vitamin D Receptor

Pages listed in BOTH of the categories Cognition and Vitamin D Binding Protein


Attached files

ID Name Comment Uploaded Size Downloads
7296 Taql VDR Alz.pdf PDF 2016 admin 05 Nov, 2016 17:58 957.34 Kb 287
5903 AD 2.jpg admin 10 Sep, 2015 13:16 66.58 Kb 1214
5902 AD 1.jpg admin 10 Sep, 2015 13:15 73.11 Kb 2034
5901 Vitamin D and Alzheimer’s Disease.pdf PDF 2015 admin 10 Sep, 2015 13:15 2.46 Mb 706
See any problem with this page? Report it (FINALLY WORKS)